Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 506414 | NSE Symbol : | ISIN : INE225B01021 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
21-May-2025	28-May-2025	Final Dividend	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 inter alia to consider and approve audited financial results for FY ended March 31 2025; consideration of dividend if any; approval of ESOP scheme Audited financial results for FY ended March 31, 2025 and dividend ESOP scheme, re-appointment of directors, appointment of secretarial auditor (As Per BSE Announcement Dated on :28.05.2025)
04-Feb-2025	11-Feb-2025	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve the unaudited financial results of the Company (standalone and consolidated) for the quarter and nine months ended December 31 2024. Unaudited financial results for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 11/02/2025)
07-Nov-2024	14-Nov-2024	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve unaudited financial results for the quarter and half year ended September 30 2024 Unaudited financial results for quarter and half year ended September 30, 2024. (As per BSE Announcement dated on 14/11/2024)
05-Aug-2024	12-Aug-2024	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended June 30 2024 Unaudited financial results for the quarter ended June 30, 2024 Outcome of Board Meeting held on August 12, 2024 for unaudited financial results for quarter ended June 30, 2024. (As Per BSE Announcement Dated on 12.08.2024)
17-May-2024	27-May-2024	Final Dividend	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve Audited financial results for the financial year ended March 31 2024 and recommendation of dividend for FY 2023-24 if any. Audited financial results for the year ended March 31, 2024, AGM date and final dividend (As Per BSE Announcement Dated on 24.05.2024) Outcome of Board Meeting - Appointment of Company Secretary (As Per BSE Announcement Dated on 27.05.2024)
06-May-2024	06-May-2024	Change in Directors	Re-appointment of Mr. Krishna Datla (DIN: 00003247) as a Whole-time Director and Mr. Prashant Nagre (DIN: 09165447) as the Managing Director, and Postal Ballot intimation.
23-Mar-2024	23-Mar-2024	Change in Directors	Appointment of Chairman
01-Feb-2024	12-Feb-2024	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve unaudited financial results for quarter and nine months ended December 31 2023 We write to inform you that the Board of Directors of the Company at its meeting held on February 12, 2024 has, inter alia, approved the unaudited financial results for the quarter and nine months ended December 31, 2023 (Standalone and Consolidated) as enclosed. We are enclosing herewith the Limited Review Reports dated February 12, 2024 (along with the aforesaid Consolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, S R B C & Co. LLP, Chartered Accountants. Unaudited Financial Results for quarter and nine months ended December 31, 2023. Announcement for (1) Appointment of Additional (Independent) Director, (2) Postal Ballot, (3) Appointment of Compliance Officer and (4) Appointment of Secretarial Auditor (As Per BSE Announcement Dated on 12/02/2024)
30-Oct-2023	08-Nov-2023	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve Unaudited financial results for quarter and half year ended September 30 2023 We write to inform you that the Board of Directors of the Company at its meeting held on November 08, 2023 has, inter alia, approved the unaudited financial results for the quarter and half year ended September 30, 2023 (Standalone and Consolidated) as enclosed. We are enclosing herewith the Limited Review Reports dated November 08, 2023 (along with the aforesaid Consolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, S R B C & Co. LLP, Chartered Accountants. Fermenta Biotech Ltd (ONLINE)(081123) (As Per BSE Announcement dated on 08.11.2023)
02-Aug-2023	11-Aug-2023	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday August 11 2023 inter alia to consider and approve the unaudited financial results of the Company (standalone and consolidated) for the quarter ended June 30 20223. We write to inform you that the Board of Directors of the Company at its meeting held on August 11, 2023 has, inter alia, approved / recommended the following: (1) Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Reports (2) Annual General Meeting (AGM) Date: (3) Dividend and Record Date: (4) Dividend Payment Date: (5) Details of KMPs authorised to determine materiality of an event or information The Board has approved the unaudited financial results for quarter ended June 30, 2023 along with limited review reports thereon (As Per BSE Announcement Dated on 11.08.2023)
22-May-2023	29-May-2023	Accounts	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday May 29 2023 inter alia: (i) to consider and approve the audited financial results of the Company (standalone and consolidated) for the quarter and financial year ended March 31 2023; and (ii) to consider and recommend final equity dividend if any for the financial year 2022-23. We write to inform you that the Board of Directors of the Company at its meeting held on May 29, 2023 has, inter alia: 1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2023 as per Regulation 33 of the Listing Regulations. The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2023 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, S R B C & Co. LLP, Chartered Accountants, dated May 29, 2023 are enclosed herewith. 2. Recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5/- each for the financial year ended March 31, 2023 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately once the Annual General Meeting date is decided by the Board of Directors.) (As Per BSE Announcement Dated on 29/05/2023)
02-Feb-2023	10-Feb-2023	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 inter alia to consider and approve Meeting of the Board of Directors of the Company is scheduled to be held on Friday February 10 2023 inter alia to consider and approve the unaudited financial results of the Company (standalone and consolidated) for the quarter and nine months ended December 31 2022. We write to inform you that the Board of Directors of the Company at its meeting held on February 10, 2023 has, inter alia, approved the unaudited financial results for the quarter and nine months ended December 31, 2022 (Standalone and Consolidated) as enclosed. We are enclosing herewith the Limited Review Report dated February 10, 2023 (along with the aforesaid Consolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, S R B C & Co. LLP. Kindly take the above on record. The Board meeting commenced at 11.45 a.m. and concluded at 01.00 p.m. (As per BSE Announcement Dated on 10/02/2023)
02-Nov-2022	11-Nov-2022	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Pursuant to Regulation 29 of Listing Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday November 11 2022 inter alia to consider and approve the unaudited financial results of the Company (standalone and consolidated) for the quarter and half year ended September 30 2022. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 the Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders and in terms of BSE Circular LIST/COMP/01/2019-20 dated April 2 2019 the Trading Window' (period for trading in Companys securities) has been closed with effect from October 1 2022 and shall continue to remain closed till 48 hours after declaration of unaudited financial results for the quarter and half year ended September 30 2022. We write to inform you that the Board of Directors of the Company at its meeting held on November 11, 2022 has, inter alia, approved the unaudited financial results for the quarter and half year ended September 30, 2022 (Standalone and Consolidated) as enclosed. We are enclosing herewith the Limited Review Report dated November 11, 2022 (along with the aforesaid Consolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, S R B C & Co. LLP. Kindly take the above on record. The Board meeting commenced at 11.45 a.m. and concluded at 02.55 p.m. (As Per BSE Announcement dated on 11.11.2022)
05-Aug-2022	12-Aug-2022	Quarterly Results	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2022 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday August 12 2022 inter alia to consider and approve the unaudited financial results of the Company (standalone and consolidated) for the quarter ended June 30 2022. In accordance with the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 the Companys Code of Conduct to Regulate Monitor and Report Trading by Insiders and in terms of BSE Circular LIST/COMP/01/2019-20 dated April 2 2019 the Trading Window' (period for trading in Companys securities) has been closed with effect from July 1 2022 and shall continue to remain closed till 48 hours after declaration of unaudited financial results for the quarter ended June 30 2022. We write to inform you that the Board of Directors of the Company at its meeting held on August 12, 2022 has, inter alia, approved the unaudited financial results for the quarter ended June 30, 2022 (Standalone and Consolidated) as enclosed. We are enclosing herewith the Limited Review Report dated August 12, 2022 (along with the aforesaid onsolidated and Standalone unaudited financial Results) issued by the Company's Statutory Auditors, Deloitte Haskins & Sells LLP. Kindly take the above on record. The Board meeting commenced at 11.15 a.m. and concluded at 11.50 a.m. (As per BSE Announcement Dated on 12/08/2022)
23-May-2022	30-May-2022	Accounts	Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday May 30 2022 inter alia: (i) to consider and approve the audited financial results of the Company (standalone and consolidated) for the quarter and financial year ended March 31 2022; and (ii) to consider and recommend final equity dividend if any for the financial year 2021-22. Fermenta Biotech Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 30, 2022, inter alia, has recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5 each for the financial year ended March 31, 2022 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately). We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia: 1. Approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 as per Regulation 33 of the Listing Regulations. The Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2022 along with the Auditors' Reports with unmodified opinion on the aforesaid Audited Financial Results (Standalone and Consolidated) issued by the Statutory Auditors, Deloitte Haskins & Sells, LLP, Chartered Accountants, dated May 30, 2022 are enclosed herewith. 2. Recommended final equity dividend @ Rs. 1.25/- per equity share (25%) of Rs. 5 each for the financial year ended March 31, 2022 for members' approval. (Date of dispatch/payment of the aforesaid final equity dividend shall be announced separately). The Board meeting commenced at 12.30 p.m. and concluded at 03.20 p.m. We write to inform you that the Board of Directors of the Company at its meeting held on May 30, 2022 has, inter alia, approved / recommended the following: 1. Annual General Meeting (AGM) Date, 2. Dividend and Record Date, 3. Dividend Payment Date, 4. Appointment of new Statutory Auditors, 5. Appointment of Mr. Pramod Kasat (DIN: 00819790) as an Additional Director w.e.f. May 30, 2022 to hold office till the conclusion of ensuing 70th AGM., 6. Appointment of Mr. Pramod Kasat (DIN: 00819790) as an Independent Director for a period of 5 years w.e.f. August 12, 2022, subject to members' approval at the 70th AGM, 7. Re-appointment of Mr. Satish Varma (DIN: 00003255) as an Executive Director of the Company for a period of 3 years w.e.f. September 27, 2022, subject to members' approval at the 70th AGM, 8. Re-appointment of Ms. Anupama Datla Desai (DIN: 00217027) as an Executive Director of Company for a period of 3 years w.e.f. September 27, 2022, subject to members' approval at 70th AGM (As Per BSE Announcement Dated 30.05.2022) Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation given vide our letter dated May 30, 2022, regarding declaration of Audited Financial Results for the quarter and financial year ended March 31, 2022, we are enclosing herewith photocopy of the newspaper publications published in Business Standard, Mumbai (English version) on page no. 13 and in Sakal, Mumbai (Marathi version) on page no. 11 dated May 31, 2022 for your reference and record. (As Per BSE Announcement Dated on 31/05/2022)

1 2

LOGIN HERE

Fermenta Biotech Ltd

Board Meeting